Hoth Therapeutics and Washington University have agreed to extend preclinical research into HT-ALZ, Hoth’s experimental therapy for Alzheimer’s disease.
Articles by Marisa Wexler, MS
Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower…
The U.S. Food and Drug Administration (FDA) has granted marketing permission to a new test that checks for amyloid plaques…
Biogen is eliminating corporate infrastructure that had been put in place to support sales of Aduhelm (aducanumab) in…
A standardized MRI protocol to screen for brain imaging abnormalities in people with Alzheimer’s who are being treated with…
Biogen has withdrawn its application seeking approval of Aduhelm (aducanumab) to treat early Alzheimer’s disease in the European Union. A…
The Centers for Medicare and Medicaid Services (CMS), in a final national policy decision, is allowing Medicare to cover the…
Most adults in the U.S., as well as many doctors, have difficulty distinguishing between the early stages of Alzheimer’s…
Fosgonimeton, an experimental therapy Athira Pharma is developing to treat Alzheimer’s disease, was well-tolerated overall in a Phase 1…
Although the vast majority of older Americans are concerned about Alzheimer’s disease, most are unaware of Aduhelm (aducanumab),…